Recent FDA Inspection Findings and Trends
|
|
- Nicholas Parrish
- 6 years ago
- Views:
Transcription
1 Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Jul-11 Aug-11 Sep-11 Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 6/21/2012 Recent FDA Inspection Findings and Trends Jennifer DeMatteo, MCM, CIC EBAA Director of Regulations and Standards EBAA Medical Standards B1.200 Inspections by Official Agencies Any written documentation of observations, findings, or results (including but not limited to Food and Drug Administration (FDA) Form 483) received by an eye bank which are related to any inspection by an official agency shall be sent to the EBAA office and the Chair of the Accreditation Board within ten (10) business days of receipt. The EBAA office and the Chair of the Accreditation Board shall be copied on all future related correspondence Regulatory Inspections Reported to the EBAA By Month Number of inspections without Observations Number of inpections with observations Regulatory Inspections By Region YTD Region Total No. of Regulatory Inspections Percentage Northeast % Southeast % Midwest % Southwest % West % Canada % TOTAL 110 1
2 Regulatory Inspections By Eye Bank Size Eye Bank Size YTD Small Medium Large Total Regulatory Observations Number of Regulatory Observations YTD 6% 6% 8% 4% 6% 1% 1% 3% 65% No 483 Issued 1 observation 2 observations 3 observations 4 observations 5 observations 6 observations 7 observations 8 observations Top Ten Observations Found During Eye Bank Inspections YTD 21 CFR Count Description Procedures Quality Program Environmental Controls & Monitoring Donor Eligibility Records Process Validation Donor Eligibility Procedures Storage Receipt and Distribution Reporting Equipment (a) Procedures Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not established, maintained, defined, documented, implemented, followed, reviewed, revised. Specifically, * 2
3 (a) Procedures SOPM lacked procedures for: Adverse reaction reporting Error and accident reporting (HCT/P deviations) Archived specimens Procedure for testing both infant donor and mother Validation of insulated transport boxes Receipt, storage and release of ocular tissue for research & education Physical exam of ocular donors (a) Procedures Procedures were not followed: Environmental monitoring to validate processing was done in a way to prevent contamination. Dates of training completion is not recorded on training record per SOP. Entries in cleaning log and environmental culture documentation was not corrected per procedure. Gloves & gowns not worn when handling tissue per SOP Record retention Aseptic technique Supervisory approval of SOP variance Procedures SOP Maintenance SOPs are not kept up to date. SOP for lab excision doesn t reflect current practice states LFH and excisions are done in a clean room (b) Review and Approval SOP Manual doesn t contain documented approval of procedures by the director. 2 findings Establishment & Maintenance of a Quality Program A quality program which addresses all of the core CGTP requirements, appropriate for the HCT/Ps manufactured and the manufacturing steps performed, has not been established, maintained, defined, documented, implemented, followed, reviewed, revised. Specifically, *** 3
4 Quality Program Observations (a) General Expired SOPs were not removed (b)2 Procedures No procedure for the approval of the validation and verification of software. No procedure for monitoring distribution (b)3 Corrective Actions No CA s for missing recipient information No CA for incomplete autopsy findings No CA for incomplete plasma dilution sections CA for complaint about melted ice was not implemented. Quality Program Observations (b)6 HCT/P Deviations No investigation when med/soc history SOP was not followed Investigation of error in marking pre-transfusion blood samples did not correct written specifications for adequacy of specimens or include test inserts and lab procedures Investigation of inadequate sterilization did not include CA s review of time/temp before use of equipment and change in SOP (c) Audits Periodic quality audits were not performed, specifically audits of establishment performing DRAI. (x2) No RCA or follow-up audit performed for issues with storage/monitoring of supplies or tissue found without a donor number. Periodic audit by direct observation not performed Environmental Controls and Monitoring (a) Environmental Control Didn t provide adequate temperature control. No explanation or CA for out-of-range temperatures (c) Environmental Monitoring No monitoring of environmental conditions for microorganisms before, during, and after processing corneas. (x2) No rationale for 25 CFU threshold for settling plates within LFH or used for touch plates. Microbial monitoring doesn t specify which organisms warrant investigation Environmental Controls and Monitoring (d) Records Documentation of environmental controls/monitoring was not maintained ATTEST documentation not maintained. 14 of 16 biological indicators for adequacy of sterilization of processing equipment were read at less than the hour required. SOP on biological contamination control directs sampling take place according to two diagrams, which aren t included in the procedure. 4
5 Donor Eligibility Records (a) Accompanying Records No DE or slit lamp evaluation documentation accompanied tissue - EB contracts with another facility for evaluation and release of tissue (b) Summary of Records Accession numbers for specimens not kept in a logbook Documentation of name/address of communicable disease testing lab not maintained Donor Eligibility Records (d) Record Retention Requirements Records were not retained for 10 years (x3) Third party records used for DE were destroyed 6 months after DE was determined and quality reviews were complete. Records were purged after DE determined and tissues were distributed. Deleted with DE document and failed to retain a paper record in the donor file. Contracted establishment purges all paper, computer, and tape records w/in 30 days. No documentation to explain why donor was accepted when there were possible contraindications DE records were not accurate, indelible, and legible Numerous (9 of 25) discrepancies between recording and hard copy questionnaire Process Validation Procedures to validate and approve processes that cannot be fully verified by inspection and tests were not established, defined, and documented. Specifically *** Process Validation EK precuts were not validated to ensure no microbial contamination before, during, and after cutting corneas (x3) Tissue transfer from one storage chamber/media vial to another is not validated. No SOP exists describing steps for freezing scleral tissue until tissue is thawed and fully processed/preserved. Validation of tissue cultures doesn t assess antibiotics in media to prevent false positive cultures. A validated process that was changed was not reviewed, evaluated, and revalidated, Specifically, the electronic system used for labels was not revalidated. 5
6 Donor Eligibility Procedures Procedures for all steps in testing, screening, and DE determination were not established, maintained, defined, documented, implemented, followed, reviewed, revised. Specifically, *** Distribution SOP mentions a form and not the software database currently used. DE procedures were not followed (x3) Tissues from a donor with bacteremia and another with a pig valve were released. Didn t follow Physician Consultation procedure and used consults from a 3 rd party MD who was not involved in the donor s care to support acceptance of the donor. Abbreviated med/soc questions Corneas recovered despite military travel and sepsis documentation Donor Eligibility Procedures (d) Departures from procedures No justification recorded for deviating from donor eligibility procedures. A determination that a BPD did not increase the risk of disease transmission was not made by a responsible person prior to distribution. Specifically, DRAI indicates that donor received blood products prior to death, but there is no further documentation or medical record review. There was verbal information regarding 1000 ml NS, but no medical records were obtained to verify volume Storage (b) Temperature Temperature verification of insulated eye box not performed (d) Corrective Action No report or CA taken when refrigerator temperature were out of range. No documentation of CA when corneal shipment was delayed due to winter weather no assurances that temperature was maintained (e) Acceptable Temperature Limits Storage temperature for media refrigerator not recorded for one week. Recorded storage temperatures not routinely reviewed to ensure temps are w/in acceptable limits. No documented comparison between digital display, temp chart recorder, and manual thermometer per SOP. No scientific documentation for storage at -70 C Receipt and Distribution (a) Receipt - No documentation of eye tissue inspection & condition of returned tissues for damage or contamination (c) Availability for Distribution Tissues sent out for processing before distribution did not have a review of manufacturing and tracking records prior to release. Release criteria not verified before tissue made available for distribution. Documentation shows tissue was shipped on March 2 but DE determination was Mar 3 due to paper and electronic documentation (d) Packaging and Shipping - no validation of insulated transport boxes (e) Procedures Procedure does not specify quantity of ice to place in shipping container (f) Return to inventory Neither the Procedure nor Assessment Form mentions that a media color change may be indicative of bacterial contamination. 6
7 Equipment Reporting (b) Procedures and schedules Dates not recorded on temperature monitoring charts Biological indicator results recorded at different time intervals than SOP requires; documentation indicates not read at the correct time, often days later. No instructions for calculating acceptable centrifuge calibration ranges (e) Records SOP states that LFH cleaned once a week and before and after each use but no documentation found for cleaning before processing use on 3 occasions. Failure to document reasons and troubleshooting for sterilization cycle failure. Failure to document centrifuge calibration. Adverse reactions SOP did not include notification and reporting HCT/P deviations were not reported to the FDA (x2) Temperature control deviation Shipment delay Error/accidents not detected prior to tissue release were not reported to the state Med/soc questions were unanswered. Deviations related to distributed HCT/Ps were not investigated after a shipment delay. Less Frequent 483 Observations (c) Manufacturing Agreements Contracted donor screening but did not verify that scanned questionnaire matched original form or that the interview matches the audiotape Personnel SOP doesn t delineate the person responsible for each procedure. SOPM doesn t contain protocol for periodic review by user personnel no documented review in training file of QA personnel. No training documentation on updated P&Ps for out of town technicians. Personnel have not been trained as necessary to perform their assigned responsibilities. Multiple instances of failure to log tissue recoveries and no training documentation for the use of this form in training files Facilities Facility did not provide adequate plumbing with hot water. FDA Form 483 Observations Supplies and Reagents Supplies / reagents not stored per manufacturers instructions (x2) Supplies / reagents were used before they were verified to meet specifications (x2) Expired reagent used to clean BSC prior to tissue processing; temperature storage issue Processing and Process Controls Technician contaminated sterile forceps with wet autoclaved turbine box during corneal processing Labeling Controls Discrepancy found between donor ID number and cornea ID number Labels on coolers missing a label that they contain human tissue Package insert didn t include all required information 7
8 Records No agreement with processing eye bank listing names, addresses, services, and responsibilities of that establishment. SOP not followed regarding timeframes of reporting and investigation of NCR, lacked dates and signatures, NCRs without root cause identified or further investigation conducted Tracking Tracking system did not document disposition of each tissue. Tissue discard log didn t account for 15 discarded corneas; they were instead documented within each donor s file Complaint File Complaints received were not maintained in a file designated for complaints. Complaint file contained insufficient info for review & evaluation no RCA performed; surgeon was not notified Complaints were not reviewed and evaluated to determine if complaint was related to a deviation or AR. No investigation documented for complaint related to an AR, and no Medical Director review/evaluation Donor Eligibility Determination No SOP for DE determination and delegated authority Med/soc history forms screen wrong time frame for receipt of human-derived pituitary growth hormone. Pediatric donor suitability questions asked of mother but not donor regarding sexual history and incarceration Quarantine Quarantined tissue not labeled as required Tissue shipped for processing was not shipped in quarantine Donor Screening and Donor Testing A second DRAI performed but not maintained by firm or contractor. Donors with risk factors were not determined to be ineligible; specifically hepatitis history and bovine heart valve. RPR testing done on plasma samples stored longer than 48 hrs. Less Frequent Observations Registration Changes Failure to notify State DOH of changes in registration information (address change) within 30 days Bloodborne Pathogens Failure to label storage area with the universal biohazard sign. 8
APPLICATION FOR SITE INSPECTION Eye Bank Association of America
APPLICATION FOR SITE INSPECTION Eye Bank Association of America Complete this application to begin the process for inspection and accreditation by the Eye Bank Association of America (EBAA). See the EBAA
More informationQuality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018
Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General
More informationSECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including:
NT-L1.000 QUALITY ASSURANCE PROGRAM All NADOs shall have a QA Program. Current (2 nd Edition) NT-L1.100 BASIC ELEMENTS SECTION L QUALITY ASSURANCE The QA program shall include, at a minimum: 1) designating
More informationHCT/P Deviations & Reporting. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017
HCT/P Deviations & Reporting CASE STUDIES FROM TISSUE AND EYE BANKS AND CELLULAR THERAPY. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017 Tissue Bank Perspective Ashley
More informationHow to Survive an EBAA Site Inspection
How to Survive an EBAA Site Inspection Woodford S. Van Meter,MD Lexington, KY EBAA Site Inspections: Scheduled by Accreditation Board Approximately 15-20 eyebanks inspected every six months Individual
More informationHuman Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia
TITLE / DESCRIPTION: DEPARTMENT: Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia Surgical Services PERSONNEL:
More informationQuality Program: Supplies and Reagents
Quality Program: Supplies and Reagents J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ) Supervisor, Quality Assurance and Regulatory Affairs Department of Transfusion Medicine, Clinical Center, NIH Disclosures:
More informationReporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc.
Reporting Deviations of Biological Products and HCT/Ps Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Relevant Legislation Public Health Service (PHS) Act Regulates biological products
More informationUNCONTROLLED COPY WHEN PRINTED
1. PURPOSE 1.1. The purpose of this procedure is to define the steps to be followed and the responsibility for raising a nonconformance/deviation report where material/product or processes do not comply
More information21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.
Pt. 820 device together with an explanation of the basis for the estimate; (iv) Information describing the applicant s clinical experience with the device since the HDE was initially approved. This information
More informationSECTION H LABELING, PACKAGING, TRANSPORT AND DISTRIBUTION
SECTION H LABELING, PACKAGING, TRANSPORT AND DISTRIBUTION NT-H1.000 LABELS AND LABELING NT-H1.100 NOMENCLATURE Nomenclature used to describe NAM for education and/or research shall be specified in the
More informationError Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems,
Error Management and BPD Reporting for the Transfusion Service Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Objectives Define biological product deviation Explain what constitutes
More informationPART 820 QUALITY SYSTEM REGULATION. 21 CFR Ch. I ( Edition)
814.126 (b) Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of
More informationSharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016
Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY June 7, 2016 1 Brief description of the Mount Sinai Cellular Therapy Laboratory Overview of BM transplant
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Puget Sound Blood
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation
More informationFACT Common Standards for Cellular Therapies, Second Edition. Summary of Changes
FACT Common Standards for Cellular Therapies, Second Edition Summary of Changes This document summarizes major changes made to the Second Edition FACT Common Standards for Cellular Therapies. This summary
More information21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance
21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating
More informationUNCONTROLLED DOCUMENT WHEN PRINTED
1. PURPOSE 1.1. The purpose of this procedure is to provide for a system and instructions, and to assign responsibilities for receiving, processing, and investigating customer complaints. 2. APPLICATION
More informationChallenges In Cell Product Labeling, Tracking And Traceability
Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 8 Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Center for Biologics Evaluation
More informationFood and Drug Administration, HHS Pt Sec Scope Definitions Quality system.
Food and Drug Administration, HHS Pt. 820 authorized designee. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm
More informationSafa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues. Pharma Conference February
Safa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues Pharma Conference February 2017 1 Background HCT/P regulatory framework Definitions & exceptions Establishment registration-
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationOklahoma Checklist (OK)
SubHeader : 01 General Information 001 Laboratory Name: OAC 252:301-1 002 Address: 003 Phone/Fax Number: 004 Date: 005 Primary POC: 006 Email/Website: 007 *Applicable to laboratories, which have performed
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Dabur Oncology PLC hhsbluebird Department of Health and Human Services Warning Letter Public Health Service Food and Drug
More informationStandard Operating Procedure Title: Initial Investigation of Out of Specification (OOS) Results in Microbiological Laboratory
Department Micro Laboratory Document no MICLAB 145 Title 1.0 DOCUMENT OWNER Laboratory/Quality Manager 2.0 PURPOSE To establish a procedure for the investigation of initial out-of-specification (OOS) or
More informationENVIRONMENTAL HEALTH BUREAU POTABLE WATER MANAGEMENT PLAN AUDIT GUIDE
ENVIRONMENTAL HEALTH BUREAU POTABLE WATER MANAGEMENT PLAN AUDIT GUIDE June 2011 ii Table of Contents 1.0 INTRODUCTION... 5 2.0 AUDIT PROCESS... 5 2.1 Health Canada Audit Process for Potable Water on Aircraft...
More informationFDA Inspections: FDA Inspections: An Overview Overview
FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an
More informationCommon AABB Assessment Findings
Common AABB Assessment Findings Linda Sigg, MT(ASCP)SBB, CQA(ASQ) Staff Lead Assessor, Accreditation and Quality AABB Southeastern Area Blood Bankers Association Annual Meeting March 4-5, 2009 Introduction
More informationCTO Establishment Inspections. an Atlantic update - Organs
Transplant Atlantic CTO Establishment Inspections an Atlantic update - Organs October 14, 2010 Scope of Inspections All CTO establishments must be registered with Health Canada with the exception of establishments
More informationMartha A Wells, MPH Division of Human Tissues OCTGT, CBER, FDA. Pharma Conference HCT/P Meeting January 24, 2007 San Antonio, TX
Guidance for Industry: Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered From Donors Who Were Tested For Communicable Diseases Using Pooled Specimens or Diagnostic
More informationLicense Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis
License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis Purpose: To provide guidance when submitting documentation to FDA in support of a BLA or a license supplement. Definitions
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationIssue Date: Effective Date:
Page 1 of 5 TITLE: STANDARD OPERATING PROCEDURE FOR BIOLOGICAL SAFETY CABINET CLASS I and CLASS II OPERATION AND MAINTENANCE CHAPTER: SOP #: 3-Equipment SF-3-05.02 Issue Date: Effective Date: SUPERSEDES
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationPage 2 of 6 recover and, since the alarm was acknowledged fails to re-alarm. The unit is found at -5 o C the following day.
SOP SF-1-9.04 SOP for Deviation Management Page 2 of 6 recover and, since the alarm was acknowledged fails to re-alarm. The unit is found at -5 o C the following day. 3.1.3. Example of a Deviation not
More informationNational Shellfish Sanitation Program (NSSP) Guide for the Control of Molluscan Shellfish: 2017 Revision
PUBLIC HEALTH SERVICE U.S. FOOD AND DRUG ADMINISTRATION OFFICE OF FOOD SAFETY SHELLFISH AND AQUACULTURE POLICY BRANCH 5001 CAMPUS DRIVE COLLEGE PARK, MD 20740-3835 TEL. 240-402-2151/2055/4960 FAX 301-436-2601
More informationIDT Australia Ltd. 5/23/18
IDT Australia Ltd. 5/23/18 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-55 Return Receipt Requested May 23, 2018 Dr. Graeme R. Kaufman CEO, Acting, and Chairman of the
More informationQuality Management. Carlos Bachier, MD
Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory
More informationJanuary 31, 2006 CERTIFIED MAIL RETURN RECEIPT REQUESTED
January 31, 2006 CERTIFIED MAIL RETURN RECEIPT REQUESTED Michael Mastromarino, D.D.S. CEO & Executive Director of Operations Biomedical Tissue Services, Ltd. 2125 Center Avenue, Suite 300 Fort Lee, NJ
More informationAllergy Laboratories, Inc. 10/4/13
Allergy Laboratories, Inc. 10/4/13 SEP 04, 2013 Department of Health and Human Services Public Health Service Food and Drug Administration Office of Regulatory Affairs 12420 Parklawn Drive ELEM-2152 Rockville,
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations National Genetics Institute 17-Jan-06 Department of Health and Human Services Public Health Service Food and Drug Administration Los Angeles
More informationQuality Management System
Quality Management System ZYQ Testing Laboratory 11111 Testing Avenue Testing Town, Alaska 22222 (555) 555-5555 Date Prepared: April 03, 2017 Please note that this Quality Management System (QM) was originated
More informationBasic Good Laboratory Practice. Christopher Jerome, B.Vet.Med., Ph.D
Basic Good Laboratory Practice Christopher Jerome, B.Vet.Med., Ph.D Goals Outline the concept of Good Laboratory Practice (GLP) Provide some specific guidelines applicable to day to day work in the laboratory
More informationQuality Management System
Quality Management System ZYQ Testing Laboratory 11111 Testing Avenue Testing Town, Alaska 22222 (555) 555-5555 Date Prepared: January 19, 2009 1 Please note that this Quality Management System (QM) was
More informationInspections, Compliance, Enforcement, and Criminal Investigations
1 of 6 6/10/2009 10:36 AM Inspections, Compliance, Enforcement, and Criminal Investigations hhsbluebirddepartment of Health and Human Services Public Health Service Food and Drug Administration Dallas
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationSTORAGE AND HANDLING OF RED BLOOD CELLS A. GENERAL STORAGE REQUIREMENTS: 1. Uncrossmatched Red Blood Cells separated by blood group and Rh type,
I. STORAGE OF RED BLOOD CELLS: A. GENERAL STORAGE REQUIREMENTS: The temperature in all areas of a refrigerator used for the storage of Red Blood Cells must be maintained between 1 and 6 C, and should have
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationQuality System Regulation (QSR) Training
Quality System Regulation (QSR) Training Or How to Ensure Development, Production and Sale of Safe, Effective, Consistent Product FDLI February 2003 Overview QSR History, Purpose and Scope Changes from
More informationFDA > CDRH > CFR Title 21 Database Search
Seite 1 von 7 FDA Home Page CDRH Home Page Search A-Z Index 510 (k) Registration Listing Adverse Events PMA Classification CLIA CFR Title 21 Advisory Committees Assembler Recalls Guidance Standards New
More informationFACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards
FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards Inspector Name: Note: A score of 90% or higher is required to achieve active inspector status. Inspector Techniques 1. As a FACT
More informationInspection of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
COMPLIANCE PROGRAM GUIDANCE MANUAL Inspection of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) 7341.002 Implementation Date: Completion Date: when posted on-going Program/Assignment
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Thomas E. Young,
More informationMedical Standards. These Standards have the approval of the Eye Banking Committee of the American Academy of Ophthalmology.
Medical Standards These Standards have the approval of the Eye Banking Committee of the American Academy of Ophthalmology November 2013 Published by: EBAA 1015 18 th Street, NW, Suite 1010, Washington,
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration
More informationTITLE: Implantable Tissue: Receipt, Storage, Use and Documentation
PAGE 1 of 5 TITLE: Implantable Tissue: Receipt, Storage, Use and Documentation IDENTIFIER: S-FW-TS-0002 APPROVED: Executive Cabinet 2/20/18 ORIGINAL: 09/14 REVISED: 2/18 REVIEWED: EFFECTIVE DATE: 3/6/18
More informationTraffic Division Public Works Department Anchorage: Performance. Value. Results.
Mission Promote safe and efficient area-wide transportation that meets the needs of the community and the Anchorage Municipal Traffic Code requirements. Direct Services Design, operate and maintain the
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationGood manufacturing practices
ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationSustaining Our Buildings & Grounds
Sustaining Our Buildings & Grounds The Next 100 Years University of Alberta June 1 3 2008 Located Edmonton Alberta 3rd largest University in Canada 32,000 undergrads 6,000 grad students 13.9 million sq.
More informationTraffic Department Anchorage: Performance. Value. Results.
Traffic Department Anchorage: Performance. Value. Results. Mission Promote safe and efficient area-wide transportation that meets the needs of the community and the Anchorage Municipal Traffic Code requirements.
More informationCHANGES TO AATB STANDARDS FOR TISSUE BANKING, 14 TH EDITION Effective May 31, 2018 SECTION A GENERAL INFORMATION
CHANGES TO AATB STANDARDS FOR TISSUE BANKING, 14 TH EDITION Effective May 31, 2018 SECTION A GENERAL INFORMATION QUARANTINE The identification of tissue as not suitable for transplantation, including tissue
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationAmerican Association for Laboratory Accreditation
Page 1 of 34 This checklist is intended for use in association with A2LA assessments, and is not to be publicly distributed. Use of this document is restricted to A2LA employees, contractors, and applicant
More informationSensor Scientific, Inc.
Sensor Scientific, Inc. 6 Kings Bridge Road Fairfield, New Jersey Quality Manual Revised: 26 September, 2012 Authorized By: G. R. Brinley Page 1 of 21 Table of Contents Page 1. Introduction 3 2. Purpose
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationFORT KNOX. Environmental Management System Manual FORT KNOX. Environmental Management System Manual. Reference Number: Revision Date: 15NOV17 EMS-01
This is an UNCONTROLLED DOCUMENT printed 11/16/17 for reference only. The current CONTROLLED copy is available on the Environmental Management Division s webpage. Reference Number: EMS-01 Manual Approved
More informationQP Supplier Quality Requirements Manual. Purchasing. Dearborn Inc. Revision: E Page 1 of PURPOSE
Page 1 of 8 1.0 PURPOSE 1.1 The purpose of this manual is to have a single document which conveys the minimum quality requirements and manufacturing practices expected of suppliers for value added products
More informationDepartment of Transportation Rapid City Region Office 2300 Eglin Street P.O. Box 1970 Rapid City, SD Phone: 605/ FAX: 605/
Connecting South Dakota and the Nation Department of Transportation Rapid City Region Office 2300 Eglin Street P.O. Box 1970 Rapid City, SD 57709-1970 Phone: 605/394-2244 FAX: 605/394-1904 July 9, 2014
More informationZOLL Document Number: 90E0021 Page 6 of 50 QUALITY SYSTEM MANUAL ZOLL Document Number: 90E0021 Page 7 of 50 1 EXECUTIVE MANAGEMENT APPROVAL... 10 2 INTRODUCTION... 11 3 QUALITY SYSTEM... 12 3.1 QUALITY
More informationMetrics in Microbiology Monitoring Practices
Metrics in Microbiology Monitoring Practices Crystal Booth, M.M. Masters of Microbiology from North Carolina State University Former Associate Director of Microbiology at Novartis Metrics in Microbiology
More informationEquipment cleaning and use record
DOCUMENTATION Documentation is an essential part of the quality assurance system and, as such, should be related to all aspects of GMP. Its aim is to define the specifications for all materials and the
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationFacility and Equipment Maintenance
Facility and Equipment Maintenance Deborah L. Griffin Manager, Quality Assurance for Cellular Therapies Hillman Cancer Center University of Pittsburgh Cancer Institute University of Pittsburgh Medical
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationIS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing Practice PHS Act: : Public Health Service Act CFR: : Code of Federal Regulations CP: : Comp
PREPARING FOR AN FDA INSPECTION August 11, 2011 Kip J. Hanks, Investigator Biologics National Expert FDA Division of Domestic Field Investigations 1 IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE QA.APP.GEN-52 Laboratory Commodities and Consumables: Supplier Technical Questionnaire
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Laboratory Commodities and Consumables: Supplier Technical Questionnaire This questionnaire is used to collect information from offerors of Laboratory Commodities
More information4. RELATED DOCUMENTS AND FORMS 4.1. AS ISO Cambridge Valley Machining, Inc. QMS procedures, including, but not limited to:
Approved By: Purchasing Manager Candice Lane (signature on file) Date: 5/26/17 Approved By: Process Owner James D. Moore (signature on file) Date: 5/26/17 1. PURPOSE 1.1. To define Cambridge Valley Machining,
More informationSTUDY REQUEST FORM AND TRAQ DSS FORM
Research Road Map April 2017 In This Issue Pharmacy Services for Research Study Request Form and TRAQ DSS FORM Management of Investigational Drugs Pharmacy Standard Operating Procedures IDS Team Qualifications
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationThe Standard Illustrations ISO The International Standard for Quality Management Systems. Year 2000 Edition. Leland R.
ISO 9001 The Standard Illustrations The International Standard for Quality Management Systems Year 2000 Edition Leland R. Beaumont ISO 9001, The Standard Illustrations Figures excerpted from ISO 9001,
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationPART 610 GENERAL BIOLOGICAL PRODUCTS STANDARDS. Subpart A Release Requirements. 21 CFR Ch. I ( Edition) Subpart G Labeling Standards
Pt. 610 and that are licensed under section 351 of the Public Health Service Act, as well as licensed biological products used in the manufacture of a licensed device, must register and list following
More informationMEDICAL ADVISORY BOARD MEETING MINUTES Eye Bank Association of America Thursday, November 12, :00pm 4:00pm Caesar s Palace, Las Vegas, NV
MEDICAL ADVISORY BOARD MEETING MINUTES Eye Bank Association of America Thursday, November 12, 2015 1:00pm 4:00pm Caesar s Palace, Las Vegas, NV I. Call to Order Dr. Michael Nordlund called the meeting
More informationProcurement Quality Assurance Requirements
1. REQUIREMENTS 1.1 Quality System This document provides the minimum Quality System Requirements to externally provided processes, products and services to Superior Thread Rolling (STR). Suppliers must
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationMonitoring validated processes by using SPC
Monitoring validated processes by using SPC Content Monitoring validated process effectively Using SPC / Control charts to monitor processes Separating Signal from Noise System Approach Risk Analysis Protocol/Report
More information